What are the NCCN recommendations for consolidation therapy for non-small cell lung cancer (NSCLC) stage III?

Updated: Jul 15, 2021
  • Author: Marvaretta M Stevenson, MD; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print


Following concurrent chemotherapy and radiation therapy, National Comprehensive Cancer Network guidelines recommend consolidation therapy with durvalumab for stage III disease. [7]

Durvalumab is given as follows for up to 12 months [27] :

  • Patients weighing ≥30 kg: 10 mg/kg IV q2wk or 1500 mg IV q4wk infused over 60 min 
  • Patients weighing < 30 kg: 10 mg/kg IV q2wk infused over 60 min 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!